Status:
COMPLETED
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
Lead Sponsor:
Western University of Health Sciences
Collaborating Sponsors:
American College of Clinical Pharmacy
Conditions:
Acute Decompensated Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion dur...
Detailed Description
No additional details provided
Eligibility Criteria
Inclusion
- At least 18 years of age.
- Subject must be able to understand the potential risks and benefits associated with the study.
- Baseline systolic blood pressure ≥ 90 mm Hg at the time of enrollment.
- Clinical symptoms of dyspnea and laboratory admission BNP levels \> 500 pg/mL.
- Neither pregnant or breastfeeding at the time of enrollment.
- Authorization of patient's enrollment by patient's medical provider.
Exclusion
- \<18 years of age
- Denies written informed consent
- Pregnant or lactating.
- Baseline systolic BP \< 90 mmHg or cardiogenic shock
- No symptoms of congestion or admission BNP \< 500 pg/mL
- Known allergy to E.coli-derived products, or any history of anaphylactic reactions to nesiritide.
- Receiving dialysis at the time of enrollment.
- Serum creatinine \> 2.5 mg/dL at the time of enrollment.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT00842023
Start Date
July 1 2006
End Date
February 1 2009
Last Update
August 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centinela Hospital Medical Center
Inglewood, California, United States, 90301